Sanofi's eczema drug is four-time blockbuster

Sanofi drug Dupixent, which Leo Pharma hopes to challenge with its tralokinumab treatment, has surpassed USD 4bn in sales.

Photo: Gonzalo Fuentes/Reuters/Ritzau Scanpix

The resurgence of the coronavirus in many countries has not put a damper on the growth of Sanofi's eczema drug Dupixent.

In the fourth quarter, sales of the biological drug's sales have increased by more than 50 percent, causing it to pull in revenue of just under USD 1bn. For all of 2020, Sanofi has scraped together around EUR 3.5bn (USD 4.2bn), which adds up to a 74-percent increase compared with 2019.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs